This study also showed an almost 50% increase in gout and cholelithiasis. "The incidences of gout and cholelithiasis were higher with bempedoic acid than with placebo (3.1% vs. 2.1% and 2.2% vs. 1.2%, respectively)," Cholelithiasis is gallstones.

True!

Thank you for the info. I hope those results added to the recent positive developments will move the PPS up nicely.

I have not been following this board as closely as in the past. What ever happened to the study in Brazil to see the effect of Vacsepa on Covid patients? The reason I am asking was this from Forbes today. "An inescapable conclusion is that vaccines alone are not an effective Covid-19 strategy. Therapeutics are needed. We now have a brief window of opportunity to identify and stockpile effective therapeutics. Even as we continue to strive for greater vaccination compliance, we must redouble our efforts to make therapeutics to treat the damaging effects of Covid-19 available, no matter how the virus evolves. The sooner we recognize and address this need, the sooner we will be able to direct our future. Failure to do so will condemn us to a never-ending cycle of chasing a shape-shifting pathogen."

Barely, but now sales are dropping as generics ramp up.

Totally agree. We will never stop losing money and will need a big capital raise just to stay in business. No potential buyer wants to see a sea of red every quarter.

Amarin is derisked to the down side, but unable to get out of this rut on the up side. Amarin should split into US only and ROW. They should then sell ROW and distribute that as a dividend to shareholders. Then in the US, they should lay off the sales force and cease advertising. They should still sell in the US and continue the legal fight. This will take years to play out and if they win, they will get a huge payout from the generics.

Is there any chance that Amarin gets any of that new government funding for companies that will lessen the severe Covid effects?

Is there anything that would prevent GILD from using generic Vascepa if there is no change in the patent situation that currently exists?

Check out the Novavax vaccine. A clinical trial in the UK found it slightly better than Moderena on the original Covid-19 strain and 85% effective against the UK strain. The US clinical trial should be done soon. Hopefully this will be approved soon(I put some of the money from the sale of half my Amarin shares after Reduce-It results into this stock.

Thank you marjac for all your tireless efforts on our behalf!

Totally agree. They should do it now as this would have more of a bounce than any Covid angle. They already have data for statins and no Vascepa from the Reduce-It control group.


























a control group of statin users without Vascepa from Reduce-It

ralphey-why doesn't Amarin use some of their money on a preliminary Vascepa without statins study. You said in your excellent posting that the Reduce-It results would probably have been even better on people not taking statins. There are millions who have a high risk of CVD that are not taking statins for various reasons.

A recent study finds that only 6 percent of people prescribed statins are taking them.

Researchers have no idea why.

Statins do come with side effects, the most frequent being muscle weakness, although it affects a very small percent of people taking them.

However, a recent study did find a moderately increased risk of developing diabetes.


Let's go after this untapped market.

If they can prove the MOA of V, they can run a small study of persons with CVD who are not taking statins to show that V is still effective for that sizeable population.

Amarin should run a small trial on those who are at risk, but do not take statins for various reasons. Is there a short-term biomarker that would show effectiveness?

They need to test whether a once daily combo pill is feasible since statins are taken once daily. If the can do that, then they will have hit a grand slam. I believe that Amarin partner Mochida was testing something that might be adaptable to this.

Totally agree, but it is still a real long shot. Luckily other events are on the horizon to kick-start the share price.

I got my second Moderna shot on Wednesday. My arm was more sore than with the first shot, but nothing other than that.

I did not realize that Amarin's "main patents" were canceled. This was a very inaccurate article as usual.

I still think that a sale that would include every market but the US is the best way to go. The US is too tangled up and may take years to resolve. Basically Amarin USA only would be a patent troll hoping for a big infringement payout down the road.

dmiller, you are 100% right. I don't get these people at all. They fail to realize that you can open up a restaurant, but if half or more of the people won't go there while the risk is so great-they will not survive for long. If Vascepa is found to work with Covid this will be a huge plus for the stock.

Terrific post.

Great. Thank you.

Very interesting. I would have liked to have seen where Pharmacy, Hindu and Cardio think the price will be as they have more insights than most due to their careers.

We should also study the life expectancy of Amarin shareholders. We can see if all the grief from investing in this stock had any effect.

Mochida is currently testing a once-a-day version of EPA. They should look into a combo of that plus a statin.

They need to do a doctor survey to get the real number. They need the real number to calculate damages if it comes to that.

Totally agree. Two doctors on this board stated that 2% or fewer of their Vascepa prescriptions were for the Marine indication. The question is what to do about it. Suing Amarin management will not help.

Well done!!!

He also said that it was worth a shot at these levels. Even better at today's price.

The Novavax vaccine will be the ultimate winner of this battle. Plus they have a flu vaccine for seniors that should be approved soon. A combo Covid and flu shot is being tested by them as well.

Pharmacydude Since that is the case it opens up the treatment to those who cannot swallow a capsule for whatever reason. Do you think that Amarin will eventually release a blister pack to pharmacies for discharged Covid patients?

Can Vascepa be given in liquid form (shots, intravenous) to patients unable to swallow capsules?

Totally agree ralphey, but better late than never. They could take the results and then go to Doctors using their First Amendment court win to tout it. They could even use the Mochida one a day capsule to differentiate from generic Vascepa.

Amarin should run a small study with at risk CVD people who are not taking statins for various reasons. They could then compare the resulting biomarkers to those that were found after Reduce-It. Dr. Bhatt's post Reduce-It analyses of what Vascepa actually did to various makers is quite extensive. We need some more positive things to talk about.

What we really need is for a consumer class action law suit against Hikma for their inferior quality and disgusting taste and smell. You are paying for a generic equivalent capsule and it is not equivalent at all!

A sale for ROW should be the goal after results of the Vascepa Covid trials. An all-stock deal from a big pharma would be a great way to go. The stock could then be distributed to shareholders. Amarin would retain the US market. Since the US saga will probably play out in court for years, potential big pharma suitors for Amarin ROW would be larger than with the US included as some would not want to get involved

Thank you for the link. I found it interesting that TEVA cited Amarin v. Hikma. And brand-name companies are proving them right. Following this decision, a generic that just launched with a carve-out now faces inducement litigation, relying on indistinguishable evidence—awareness of potential direct infringement, references to the “AB rating,” and archived press releases announcing FDA approval—and demanding lost profits. Compl., ¶¶ 94-113, Amarin Pharma, Inc. v. Hikma Pharm. USA Inc., No. 20-cv-1630 (D. Del. filed Nov. 30, 2020). Generics now face “drastically increase[d] ... potential liability for launching with a skinny label,”16 with “large and meaningful damages” from lost profits “more likely.

dukesking Thanks.

I will check. Thanks.